Robert Zeldin
About Robert Zeldin
Robert K. Zeldin Chief Medical Officer
Robert K. Zeldin currently holds the position of Chief Medical Officer. His extensive experience in the medical and pharmaceutical fields has positioned him as a key player in the companies he has served. His role as a CMO has seen him leading significant clinical development programs and overseeing regulatory filings critical to the success of novel therapeutic products.
Education and Medical Training of Robert K. Zeldin
Robert K. Zeldin graduated with honors with a Bachelor of Arts from the Johns Hopkins University. He pursued his medical degree at Tufts University School of Medicine. Following his M.D., he completed a residency in Internal Medicine at the University Health Center of Pittsburgh. He further specialized in Allergy and Clinical Immunology through a fellowship at the Johns Hopkins University School of Medicine.
Professional Background of Robert K. Zeldin
Robert K. Zeldin has served in various high-level positions in the pharmaceutical industry. Notably, he was the Chief Medical Officer of Acceleron Pharma and Immunovant. He guided the Phase 3 development program and regulatory filings of caplacizumab at Ablynx NV. At Stallergenes SA, he worked as Senior Vice President and Head of Global Clinical Development. Additionally, he held a pivotal role as Vice President and U.S. Medical Franchise Head for Respiratory and Dermatology at Novartis Pharmaceuticals. His career also includes seven years at Merck in strategic roles within regulatory affairs and clinical development, as well as serving as a Medical Officer at the FDA’s Center for Biologics Evaluation and Research.
Robert K. Zeldin's Contributions to Biologic Therapies
Robert K. Zeldin has made significant contributions to the field of biologic therapies. He was instrumental in the preparation of the biologics license application for luspatercept during his tenure at Acceleron Pharma. His work also includes the successful direction of the Phase 3 development program and regulatory filings of caplacizumab at Ablynx NV. These initiatives have advanced the availability of new therapeutic options and underlined his expertise in biologics.